Athira Pharma, Inc. ATHA
We take great care to ensure that the data presented and summarized in this overview for Athira Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATHA
View all-
Perceptive Advisors LLC New York, NY5.4MShares$14.6 Million0.31% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$8.55 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$4.43 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$4.05 Million2.38% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$4.05 Million0.26% of portfolio
-
Bml Capital Management, LLC Zionsville, IN900KShares$2.44 Million1.65% of portfolio
-
Tang Capital Management LLC San Diego, CA853KShares$2.31 Million0.28% of portfolio
-
Black Rock Inc. New York, NY667KShares$1.81 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA550KShares$1.49 Million0.01% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ497KShares$1.35 Million0.01% of portfolio
Latest Institutional Activity in ATHA
Top Purchases
Top Sells
About ATHA
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Insider Transactions at ATHA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 05
2024
|
Mark James Litton CEO |
SELL
Open market or private sale
|
Direct |
4,820
-3.23%
|
$9,640
$2.91 P/Share
|
|
Jan 05
2024
|
Rachel Lenington COO AND CDO |
SELL
Open market or private sale
|
Direct |
2,412
-15.26%
|
$4,824
$2.91 P/Share
|
|
Jan 05
2024
|
Mark Worthington GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
2,412
-6.54%
|
$4,824
$2.91 P/Share
|
|
Jan 04
2024
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+9.85%
|
-
|
|
Jan 04
2024
|
Mark James Litton CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+11.82%
|
-
|
|
Jan 04
2024
|
Rachel Lenington COO AND CDO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+38.75%
|
-
|
|
Jan 04
2024
|
Mark Worthington GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+21.34%
|
-
|
|
Dec 29
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
163,954
+2.95%
|
$327,908
$2.38 P/Share
|
|
Dec 28
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
409,598
+7.25%
|
$819,196
$2.44 P/Share
|
|
Dec 27
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
32,134
+0.66%
|
$64,268
$2.28 P/Share
|
|
Nov 20
2023
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,397
+4.47%
|
$3,397
$1.34 P/Share
|
|
Jun 07
2023
|
Andrew Gengos CFO AND CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
15,000
+5.81%
|
$45,000
$3.4 P/Share
|
|
Jun 05
2023
|
Andrew Gengos CFO AND CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
45,000
+19.22%
|
$135,000
$3.01 P/Share
|
|
Jun 02
2023
|
Hans Moebius Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,882
+8.82%
|
$7,882
$1.35 P/Share
|
|
Jun 02
2023
|
Andrew Gengos CFO AND CHIEF BUSINESS OFFICER |
BUY
Open market or private purchase
|
Direct |
20,012
+31.0%
|
$40,024
$2.85 P/Share
|
|
May 18
2023
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
809
+1.15%
|
$1,618
$2.41 P/Share
|
|
May 18
2023
|
Mark Worthington GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
7,767
+22.43%
|
$15,534
$2.41 P/Share
|
|
May 18
2023
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,764
+9.54%
|
$15,528
$2.41 P/Share
|
|
Mar 30
2023
|
Grant Pickering Director |
BUY
Open market or private purchase
|
Direct |
15,000
+36.78%
|
$30,000
$2.47 P/Share
|
|
Mar 29
2023
|
Grant Pickering Director |
BUY
Open market or private purchase
|
Direct |
10,000
+48.12%
|
$20,000
$2.33 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 686K shares |
|---|---|
| Grant, award, or other acquisition | 69.7K shares |
| Exercise of conversion of derivative security | 7.88K shares |
| Open market or private sale | 9.64K shares |
|---|